Skip to content

Evaluation of novel water soluble compositions of propofol for intravenous anesthesia.

Oct 2026 · Journal of Pharmacy and Science · pp. 104558 · 0 citations · 22 references
Medicine

Abstract

Solubilizing propofol without lipid-associated risks-hyperlipidemia, microbial growth, and severe injection pain-remains a major formulation challenge spanning over four decades. Traditional lipid emulsions persist largely due to the difficulty of achieving high-capacity aqueous solubilization without compromising safety or stability. This study evaluates a fat-free, preservative-free aqueous 1% propofol formulation enabled by a novel PEG-carbohydrate-lipid conjugate, 3,3-oleoyl-monomethoxy-polyethyleneglycol (n = 12 mean) ether-propanediaminolactobionate ("DOPS-F02"), highlighting its efficiency as an advanced solubilizing excipient for intravenous delivery. Solubilization capacity was profiled alongside a 24-month GLP stability trial of 1% propofol with 2.3% DOPS-F02 in 5% dextrose (Type I glass vials). A fixed-dose combination with 0.11% lidocaine HCl was evaluated without increasing excipient concentration. Pharmacokinetic, pharmacodynamic, and nociceptive profiles (rat paw-flick/paw-lick model) were compared against commercial control (Fresofol). DOPS-F02 demonstrated exceptional solubilization efficiency, driving propofol aqueous solubility up to 80 mg/mL at a low 1:2.2 w/w drug-to-solubilizer ratio in 5% dextrose or saline. Autoclaving induced a reversible cloud-point phase transition, returning to a clear, isotropic state upon cooling. Over 24 months, potency remained within ±3% with total impurities below 0.3%. In vivo, DOPS-F02 achieved therapeutic equivalence to Fresofol (loss of righting reflex; sleep duration 7.73-7.83 min). Unlike typical non-lipid formulations that exacerbate injection pain, DOPS-F02 allowed seamless co-formulation with lidocaine without phase separation, mitigating pain to near-baseline levels. As a novel solubilization platform, DOPS-F02 resolves a multi-decade formulation hurdle, delivering a clear, lipid-free propofol system requiring only a 1:2.2 drug-to-solubilizer ratio that eliminates emulsion liabilities and injection pain.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.